Literature DB >> 17590361

Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.

Robert Hines1, Anita Boyapati, Dong-Er Zhang.   

Abstract

The AML1-ETO fusion protein is generated from the 8;21 chromosome translocation that is commonly identified in acute myeloid leukemia. AML1-ETO is a DNA binding transcription factor and has been demonstrated to play a critical role in promoting leukemogenesis. Therefore, it is important to define the molecular mechanism of AML1-ETO in the regulation of gene expression. Here, we report that the effect of AML1-ETO on the promoter of multidrug resistance-1 (MDR1) gene, a known AML1-ETO target, is highly cell type specific. Besides observing repression of the MDR1 promoter in C33A and CV-1 cells as reported previously, AML1-ETO strongly activated the promoter in K562 and B210 cells. More importantly, this activation required both the AML1 and ETO portions of the fusion protein, but did not depend on the AML1 binding site in MDR1 promoter. Furthermore, results from promoter deletion analysis and chromatin immunoprecipitation assays suggested that this activation effect was likely through the influence of the general transcription machinery rather than promoter-specific factors. Based on these data, we propose that AML1-ETO may have opposing effects on gene expression depending on the various conditions of the cellular environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17590361      PMCID: PMC2048671          DOI: 10.1016/j.bcmd.2007.05.005

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  56 in total

Review 1.  Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins.

Authors:  S W Hiebert; B Lutterbach; J Amann
Journal:  Curr Opin Hematol       Date:  2001-07       Impact factor: 3.284

Review 2.  AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

Authors:  J D Licht
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

3.  Differentiation of K562 leukemia cells along erythroid, macrophage, and megakaryocyte lineages.

Authors:  J A Sutherland; A R Turner; P Mannoni; L E McGann; J M Turc
Journal:  J Biol Response Mod       Date:  1986-06

4.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

5.  Induction of erythroid differentiation in the human leukaemia cell line K562.

Authors:  L C Andersson; M Jokinen; C G Gahmberg
Journal:  Nature       Date:  1979-03-22       Impact factor: 49.962

6.  The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.

Authors:  G Grosveld; T Verwoerd; T van Agthoven; A de Klein; K L Ramachandran; N Heisterkamp; K Stam; J Groffen
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

7.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.

Authors:  Y Yuan; L Zhou; T Miyamoto; H Iwasaki; N Harakawa; C J Hetherington; S A Burel; E Lagasse; I L Weissman; K Akashi; D E Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

8.  AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon.

Authors:  K Shimizu; I Kitabayashi; N Kamada; T Abe; N Maseki; K Suzukawa; M Ohki
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

9.  ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.

Authors:  J M Amann; J Nip; D K Strom; B Lutterbach; H Harada; N Lenny; J R Downing; S Meyers; S W Hiebert
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

10.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

Authors:  Masakazu Higuchi; Darin O'Brien; Parasakthy Kumaravelu; Noel Lenny; Eng-Juh Yeoh; James R Downing
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  5 in total

1.  PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.

Authors:  Wei-Jong Shia; Akiko J Okumura; Ming Yan; Ali Sarkeshik; Miao-Chia Lo; Shinobu Matsuura; Yukiko Komeno; Xinyang Zhao; Stephen D Nimer; John R Yates; Dong-Er Zhang
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

2.  t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.

Authors:  Akiko J Okumura; Luke F Peterson; Fumihiko Okumura; Anita Boyapati; Dong-Er Zhang
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

3.  The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.

Authors:  Rachit Bakshi; Sayyed K Zaidi; Sandhya Pande; Mohammad Q Hassan; Daniel W Young; Martin Montecino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Sci       Date:  2008-11-11       Impact factor: 5.285

4.  Hmga2 is a direct target gene of RUNX1 and regulates expansion of myeloid progenitors in mice.

Authors:  Kentson Lam; Alexander Muselman; Randal Du; Yuka Harada; Amanda G Scholl; Ming Yan; Shinobu Matsuura; Stephanie Weng; Hironori Harada; Dong-Er Zhang
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

5.  Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.

Authors:  Russell C DeKelver; Benjamin Lewin; Kentson Lam; Yukiko Komeno; Ming Yan; Chandler Rundle; Miao-Chia Lo; Dong-Er Zhang
Journal:  PLoS Genet       Date:  2013-10-10       Impact factor: 5.917

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.